Although not in BC, assays based on HRR defect signatures (which have a higher prevalence than BRCA1/2 mutations) are currently validated and in clinical use, such as HR deficiency (HRD) detect [29, 30], My choice HRD (Myriad Genetics Inc, Sault Lake City, UT, USA) [31, 32] and Foundation Focus CDxBRCA (Foundation Medicine) [33, 34]. This evidence concerns the gene BRCA1 and breast cancer.